2025-05-26 14:20R&D Strategy and Product Pipeline - The company has initiated a comprehensive review of its R&D strategy starting in 2024, focusing on clear and defined strategic lines around disease areas and technology platforms [2][3]. - In the gastrointestinal field, the company is expanding its product lineup with P-CAB tablets and injectables, with P-CAB tablets currently in Phase III clinical trials [3]. - The reproductive health sector has a complete product cycle from ovulation induction to luteal support, with a key product, recombinant human follicle-stimulating hormone injection, reported in January 2023 and expected to enhance the product pipeline [3]. - In the field of mental health, the company is advancing its pipeline with innovative products like NS-041 tablets, which have completed Phase I trials and are moving into Phase II [4]. Key Product Developments - NS-041 tablets are positioned as a best-in-class product for epilepsy, showing superior selectivity and efficacy compared to similar products in development, with a patent protection until 2042 [4]. - The small nucleic acid project LZHN2408 has completed IND filing and targets gout with high patient demand, expected to receive clinical approval soon [5]. - The IL-17A/F monoclonal antibody for psoriasis has completed Phase III clinical enrollment and is expected to launch in 2025, with promising clinical data showing a 60% complete skin clearance rate at 12 weeks [6][7]. Business Development and Market Strategy - The company employs a dual strategy of self-research and business development (BD) to enhance its pipeline, focusing on projects that align with its core areas and technology platforms [9]. - The acquisition of Vietnam's IMP company aims to strengthen innovation and global market presence, leveraging IMP's established marketing network and production capabilities [12]. - The company anticipates steady growth in its traditional Chinese medicine sector, driven by products like the ginseng and astragalus injection, benefiting from policy changes [10][11]. Organizational Changes and Efficiency - The company has enhanced its operational efficiency through systematic improvements in R&D project management, optimizing processes and resource allocation [13]. - Structural adjustments have been made to ensure a stable workforce while optimizing roles, particularly in sales, to support product launches and market penetration [13].